Introduction
tumor, liver malignancies, toxicities, TD, HCC
ADVERSE EVENTS, TUMOR
Yttrium 90 (Y90) radioembolization is a locoregional therapy that targets liver malignancies through the use of microspheres injected into the tumoral arterial bed [Additionally, with the escalation of tumor dose, radiation delivery to the rest of the liver and lungs may cause greater adverse events (AEs) [The aim of this prospective trial was twofold: (1) to determine a tumor dose (TD) threshold that predicts complete and objective tumor response and (2) to determine a NTLD threshold that can predict severe treatment-related toxicities at 3 and 6 months after resin-based Y90 radioembolization in patients with HCC.